Alumis (NASDAQ:ALMS - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Alumis to post earnings of ($1.40) per share for the quarter.
Alumis Trading Up 0.8 %
NASDAQ ALMS traded up $0.04 on Friday, reaching $5.17. 456,737 shares of the stock traded hands, compared to its average volume of 258,036. Alumis has a 12 month low of $4.74 and a 12 month high of $13.53. The company has a fifty day moving average price of $7.18 and a 200-day moving average price of $9.75.
Analysts Set New Price Targets
Several brokerages have recently weighed in on ALMS. Baird R W raised shares of Alumis to a "strong-buy" rating in a research report on Thursday, October 31st. Oppenheimer initiated coverage on Alumis in a report on Thursday, January 30th. They set an "outperform" rating and a $32.00 target price for the company. Robert W. Baird started coverage on Alumis in a report on Thursday, October 31st. They set an "outperform" rating and a $25.00 target price for the company. HC Wainwright decreased their price objective on Alumis from $26.00 to $19.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $26.57.
Read Our Latest Stock Report on ALMS
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
